secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001493152-25-007980
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04
--------------------------------------------------------------------------------

- Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.
- Cash $4.6M at Dec 31, 2024; additional $2.2M raised in Jan/Feb 2025.
- Phase 1b trial of ATR-12 in Netherton syndrome ongoing; initial safety data expected H1 2025, topline by year-end.
- FDA cleared IND and granted Fast Track for ATR-04 for EGFRi rash; multicenter Phase 1/2 to start H1 2025.
- Closed $10M and $5M public offerings in 2024; IP portfolio strengthened.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/0001493152-25-007980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer